(Circulation. 2000;101:1976.)
© 2000 American Heart Association, Inc.
Basic Science Reports |
Modulation of Functionally Active Endothelin-Converting Enzyme by Chronic Neutral Endopeptidase Inhibition in Experimental Atherosclerosis
From the Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minn, and BASF Pharma (T.S.), Ludwigshafen, Germany.
Correspondence to J. Aaron Grantham, MD, Cardiorenal Research Laboratory, Mayo Clinic, 200 First St SW, Rochester, MN 55905. E-mail grantham.aaron{at}mayo.edu
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Background—Endothelin-converting enzyme-1 (ECE-1) processes big endothelin-1 (ET-1) to ET-1, a peptide implicated in atheroma formation. ECE-1 exists in 2 isoforms (ECE-1
and ECE-1ß), the result of alternative splicing of
a common gene. Neutral endopeptidase (NEP) is a
genetically distinct metallopeptidase that degrades the
natriuretic peptides. These peptides mediate
antiproliferative and vasodilating actions. We sought to demonstrate
the distribution of the 2 ECE-1 isoforms in experimental
atherosclerosis, to determine the effects of chronic
NEP-I on plasma cGMP concentrations, vascular wall ECE-1 activity, and
ET-1 concentration, and to correlate these actions with
atheroma formation. Our hypothesis was that chronic NEP-I,
in association with augmented cGMP, would inhibit ECE-1 conversion of
big ET-1 to active ET-1, thus reducing tissue ET-1 concentrations and
associated atheroma formation.
Methods and Results—Cholesterol-fed New Zealand White
rabbits (n=8, 1% cholesterol diet) and NEP-I–treated
cholesterol-fed New Zealand White rabbits (n=8;
candoxatril, 30 mg/kg per day, Pfizer) were euthanized after 8 weeks of
feeding. ECE-1 and ECE-1ß immunoreactivity was present in the
aortas of both groups. Compared with control values, plasma cGMP
concentrations were increased (2.8±0.6 versus 8.4±1.2 pmol/mL,
P<0.05), ECE-1 activity was attenuated (68±3% versus
32±8%, P<0.05), aortic tissue ET-1 concentrations
were reduced (4.6±0.5 versus 3.2±0.3 pg/mg protein,
P<0.05), and atheroma formation was
attenuated (62±6% versus 34±5%, P<0.01) by
NEP-I.
Conclusions—These studies suggest that ECE-1 is present and functionally active in the vascular wall in atherosclerosis. Inhibition of ECE-1 by NEP-I represents a novel approach to interruption of the endothelin system in this cardiovascular disease state.
Key Words: atherosclerosis • endothelin • natriuretic peptides • vasoconstriction
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Endothelin-1 (ET-1) is a potent mitogenic1 and vasoconstricting2 factor that is activated in atherosclerosis.3 ET-1 is cleaved from the prohormone (big ET-1) by endothelin-converting enzyme-1 (ECE-1) into its biologically active form. ECE-1 exists in 2 isoforms, ECE-1
and
ECE-1ß, which are the products of alternative splicing of a
common gene.4 5 6 Recent studies have demonstrated that the
expression of the ECE-1ß isoform can be induced by cytokines
implicated in atherogenesis.7 ECE-1 is upregulated after
vascular wall injury produced by balloon inflation,8 and
ECE-1 mRNA is present in human vascular tissues from patients with
atherosclerosis and hypertension.9 Atrial, brain, and C-type natriuretic peptides constitute a family of vasodilating10 and antiproliferative11 peptides of cardiovascular cell origin, which generate cGMP in response to receptor binding on endothelial cells (ECs), vascular smooth muscle cells (VSMCs), and myocardial and renal epithelial cells.12 The natriuretic peptides have been shown to possess endothelin-inhibiting actions, underscoring their counterregulatory actions to ET-1.13 14 15 The natriuretic peptides are degraded by neutral endopeptidase (NEP), an enzyme that shares structural similarity and colocalization with ECE-1.16
We have previously characterized the presence and distribution of ECE-1
in early experimental atherosclerosis, demonstrating
the localization of ECE-1 in cells of fatty streaks.17 The
present study was designed to determine the presence and
distribution of ECE-1 and ECE-1ß by using the same model.
Furthermore, we sought to define interactions between the
natriuretic peptide system and the endothelin system by
chronically inhibiting NEP with the oral NEP-I Candoxatril (Pfizer) to
augment cGMP. We also determined the effects of chronic NEP-I on
vascular wall ECE-1, ET-1, and atheroma formation testing
the hypothesis that chronic NEP-I will inhibit the ability of ECE-1 to
convert big ET-1 to biologically active ET-1 in association with
reductions in vascular wall ET-1 concentrations and
atheroma formation.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
All animal studies were performed in accordance with the guidelines for animal use in research set forth by the American Association for Accreditation of Laboratory Animal Care and approved by the Mayo Clinic Animal Care and Use Committee
Animal Model of Hypercholesterolemic Atherosclerosis
Studies were conducted in male New Zealand White rabbits
weighing 
2 to 4 kg. Rabbits received a 1% cholesterol
diet (PMI Feeds Inc) for 8 weeks (Athero group, n=8). NEP-I–treated
rabbits also received Candoxatril (30 mg/kg per day, Pfizer) for 8
weeks (NEP-I group, n=6). Candoxatril was administered via drinking
water, and the dose was confirmed each day by assessment of water
intake. Adjustments to the daily dose were made on the basis of these
determinations. Candoxatril is a specific inhibitor of NEP,
as demonstrated in previous in vivo and in vitro
studies.18 At the end of the 8-week feeding period, each
rabbit was euthanized with an overdose of pentobarbital (30 mg/kg). The
aorta was excised from the arch to the level of the diaphragm. A
section of the descending thoracic aorta was removed and placed in
chilled Krebs-Ringer solution of the following composition (mmol/L):
NaCl 118.3, KCl 4.7, CaCl2 2.5,
MgSO4 1.2,
KH2PO4 1.2,
NaHCO3 25.0, calcium disodium edetate 0.26, and
glucose 11.1 for use in organ chamber studies. The remaining descending
thoracic aorta was cut and immediately placed in liquid nitrogen for
freezing before storage at -70°C until processing for tissue peptide
analysis. A single 4- to 6-mm ring was preserved in 10%
buffered formalin for immunohistochemical analysis. The aortic
arch was fixed in 10% buffered formalin, rinsed with distilled water,
and then stained with oil red O (2 g/12 mL) for 20 minutes. The aortic
arch from the aortic valve to the second intercostal artery was mounted
en face, and the percent plaque area was quantified by threshold
analysis using true color image analyzer software.
Immunohistochemical Staining
After fixation, the tissue was dehydrated and embedded in
paraffin. Serial sections were cut at a thickness of 6 µm. The
presence of ECE-1 and ECE-1ß isoforms in aortic tissue was
documented by a specific immunohistochemical staining technique for
each peptide.17 We used polyclonal antibodies to human
ECE-1 and ECE-1ß (BASF Pharma) with cross-reactivity to other
species raised in rabbits to assess by immunohistochemistry their
presence and distribution in vascular tissue.
Functional Studies of ECE-1 Activity in Isolated Rabbit Aorta as
Assessed by Contraction to Big-ET and ET-1
Adventitial tissue was trimmed, and the aorta was cut into 4- to
5-mm rings; care was taken to avoid touching the luminal surface. Some
rings were mechanically denuded of endothelium with a
pair of blunt forceps; care was taken not to damage the smooth muscle.
Aortic rings with and without endothelium from a single
rabbit were studied in parallel. Each ring was mounted between a fixed
point and a force transducer (UC-2, Gould Inc; Hewlett-Packard Co) in
an organ bath filled with 3.5 mL modified Krebs-Ringer solution at
37°C, which was aerated with 95% O2 and 5%
CO2. Each ring was progressively stretched to the
optimum point on the length-tension curve, as determined by the active
tension developed to potassium chloride (20 mmol/L). Maximal
contraction to 60 mmol/L KCl was then determined to confirm the
intact function of VSMCs. ET-1 (10-6.5 mol/L) or
big ET-1 (10-6.5 mol/L) was added to the bath in
the presence and absence of phosphoramidon
(10-4 mol/L). The presence or absence of
endothelium was confirmed by addition of the calcium
ionophore A23187 (10-6 mol/L). Peak response to
agonists was recorded as the percentage of the maximal KCl (60
mmol/L) response. To determine ECE-1 activity, the maximal big ET-1
response was divided by the maximal ET-1 response at equimolar
concentrations multiplied by 100 and expressed as arbitrary units.
Plasma Analysis
Arterial blood for hormone analysis was
obtained after the 8-week protocol. Plasma samples were collected from
the dorsal ear artery in heparin and EDTA tubes and immediately placed
on ice. After centrifugation at 2500 rpm at 4°C, the
plasma was decanted and stored at -20°C until analysis.
Specific plasma radioimmunoassays for ET-1 were performed as described
below. Total plasma cholesterol was assessed by the Mayo
Lipid Core Laboratory Facility.
Radioimmunoassay
Plasma and tissue ET-1 concentration was determined by the
[I125]ET-1 or [I125]big
ET-1 assay system from Phoenix Pharmaceuticals, as previously described
after supernatants were acidified with 0.5% trifluoroacetic
acid.19 The recovery of the extraction procedure was 81%
and 80%, as determined by the addition of synthetic ET-1 and big ET-1,
respectively, to plasma. Interassay and intra-assay variations for ET-1
were 9% and 5%, respectively. The minimal level of detection was 0.5
pg per tube. The cross-reactivity of ET-2, ET-3, and big ET-1 was
<5%, <3%, and <27%, respectively.
Plasma cGMP was determined by cGMP assay, as previously described,20 after the supernatants were acidified with 0.5% trifluoroacetic acid. The recovery of the extraction procedure was 90%, as determined by the addition of synthetic cGMP to plasma; interassay and intra-assay variations were 8% and 5%, respectively. The minimal level of detection was 0.5 pmol per tube.
Statistical Analysis
Results were expressed as mean±SEM. Multiple ANOVA between
conditions in organ chamber studies was analyzed by the
Bonferroni test to determine significance between groups while allowing
for multiple comparisons in a single study. Statistical comparison of
assays within groups was made by the Student paired t test,
and comparisons between groups were made by unpaired t test.
Where appropriate, data were analyzed by 1-factor ANOVA for
repeated measures followed by the Fisher least significant difference
test.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Model of Atherosclerosis and Effect of Chronic NEP-I
The Table
shows the model of
atherosclerosis and the effects of NEP-I. Plasma
cholesterol concentrations and mean arterial
pressure were not influenced by NEP-I. Chronic NEP-I augmented cGMP
concentrations, without change in plasma ET-1 concentrations but with a
30% reduction in aortic tissue ET-1 concentration.
Atheroma formation was attenuated by chronic NEP-I (62±6%
versus 34±5%, P<0.05).
|
Presence and Distribution of ECE-1 Isoforms
Immunohistochemical staining for total ECE-1, ECE-1, and
ECE-1ß is shown in Figure 1. Compared
with nonimmune controls (panels A and E), the nonselective antibody
(panels B and F) demonstrates the presence of ECE-1 in the
atherosclerotic plaques. Both ECE-1 isoforms (ECE-1, panels C and G;
ECE-1ß, panels D and H) are also present in the
atheromatous plaques. In the
cholesterol-fed rabbits (Athero group), ECE-1ß
immunoreactivity more closely parallels the nonselective antibody
immunoreactivity.
|
General Responsiveness of Isolated Aorta
There were no differences between the groups in resting tension at
the optimum point of the length-tension curve. Additionally, the
maximal tension developed to 60 mmol/L KCl was not different
(8.1±1.2 versus 8.4±0.6 g for Athero group versus NEP-I–treated
cholesterol-fed rabbits [NEP-I group], respectively;
P=NS). The calcium ionophore A23187 resulted in complete
relaxation of vessels with endothelium and no
relaxation of vessels denuded of endothelium.
Time Course of Big ET-1 and ET-1 Responses
Figure 2A is a
representative tracing of the vasoconstrictor response
to big ET-1 and ET-1 in isolated aortic rings from the Athero group in
the presence and absence of endothelium. The response
to big ET-1 was delayed compared with the response to ET-1 (time to
maximal response 64.0±5.6 versus 19.3±1.4 minutes,
P<0.001). Time to maximal contraction was not affected by
the endothelium. Phosphoramidon
completely blocked the big ET-1 response, independent of the presence
or absence of endothelium in all but 1 isolated aortic
ring in the Athero group (data not shown). In that experiment, the
maximal big ET-1 response was 18% of the maximal ET-1 response.
Phosphoramidon did not alter the ET-1 response.
|
Figure 2B
is a representative tracing of the
vasoconstrictor response to big ET-1 and ET-1 in isolated aortic rings
from the NEP-I group in the presence and absence of
endothelium. The response to big ET-1 was again delayed
compared with the response to ET-1 (time to maximal response 56.0±3.6
versus 23.0±3.1 minutes, P<0.001). Time to maximal
contraction was not affected by the endothelium and was
not different from that in the Athero group.
Phosphoramidon completely blocked the big ET-1
response, independent of the endothelium, in all
experiments in the NEP-I group and did not alter the ET-1 response.
Maximal Big ET-1 and ET-1 Response
Big ET-1 mediated a maximal vasoconstriction response of 61±3%
of the KCl maximum in the presence of endothelium and
74±6% of the KCl maximum in the absence of
endothelium. ET-1 resulted in a maximal response of
91±3% of the KCl contraction in the presence of
endothelium and 105±6% of the KCl contraction in the
absence of endothelium. In the NEP-I group, big ET-1
resulted in a maximal vasoconstriction response of 58±4%
(P=NS versus Athero group with endothelium),
which was not different from the actions of big ET-1 in the untreated
Athero group with endothelium. However, with the
endothelium removed in the NEP-I–treated group, big
ET-1–mediated contraction was only 34±10% (P<0.05 versus
Athero group without endothelium) of the maximal KCl
response, consistent with a reduction in functional ECE-1
activity. The maximal response to equimolar ET-1 was 84±2% and
104±7% of the KCl maximum in the presence and absence of
endothelium, respectively.
ECE-1 Activity as Assessed by Big ET-1–to–ET-1 Response Ratio and
Modulation by NEP-I
Figure 3 shows ECE-1 activity of the
2 groups as determined by the ratio of the big ET-1 to ET-1 response in
the presence (solid bars) and absence (open bars) of
endothelium. In the presence of
endothelium, ECE-1 activity was preserved in the NEP-I
group compared with the Athero group (65±5% [Athero group] versus
64±7% [NEP-I group], P=NS). In the absence of
endothelium, ECE-1 activity was attenuated in the NEP-I
group (68±3% [Athero group] versus 32±8% [NEP-I group],
P<0.001), consistent with a decrease in the
functional ECE-1 activity in the vascular wall free of the
endothelium.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The present study is the first, to our knowledge, to determine the isoforms of ECE-1 present in a model of early atherosclerosis. Additionally, we have confirmed the functional activity of ECE-1 in the atherosclerotic aorta as assessed by the ability of big ET-1 to mediate contraction in the isolated diseased aorta. Finally, we demonstrated, for the first time, the inhibitory properties of NEP-I on aortic ECE-1 activity, tissue and plasma ET-1 concentration, and atheroma formation in experimental atherosclerosis.
The model of atherosclerosis used in the present
study is well established and reproducible.16 21 22
Rabbits fed a 1% cholesterol diet for 8 weeks developed
fatty streaks involving 60% of the surface area of the aortic arch,
which were characterized by infiltration by lipid-laden foam cells and
VSMCs. The absence of increased circulating ET-1 is further evidence of
the early nature of this model because circulating ET-1 concentration
correlates with atherosclerosis disease
burden.23 The present study confirms and extends
previous investigations by demonstrating ECE-1 immunoreactivity in
atherosclerotic vascular tissues and by determining the presence and
distribution of the and ß isoforms of ECE-1. Shimada and
colleagues24 25 reported the expression of ECE-1 in rat
ECs and human umbilical vein ECs and, later, isolated two isoforms of
ECE-1 in humans.26 This discovery led to the development
of monoclonal ECE-1 antibodies.27 Newer antibodies to the
and ß isoforms of human ECE-1 that cross-react with other species
were used in the present study to demonstrate the presence of these
isoforms in the hypercholesterolemic rabbit. The
selective antibodies demonstrate that both the and ß isoforms of
ECE-1 are distributed in the atherosclerotic rabbit aorta. ECs, VSMCs,
and foam cells contained within atherosclerotic lesions demonstrated
ECE-1 immunoreactivity; however, it is apparent after inspection of the
immunohistochemical staining for ECE that ECE-1ß immunoreactivity
more closely parallels that of the nonselective antibody. Although no
conclusion can be drawn regarding the relative importance of these
isoforms on ET-1 production in atherosclerosis,
this observation may suggest that ECE-1ß contributes to ET-1
production in atherosclerosis. The presence of
ECE-1 immunoreactivity in atheromatous lesions is
consistent with previous reports of ECE-1 immunoreactivity and
mRNA expression in atherectomy specimens from human coronary
arteries8 and, more recently, a report by Rossi et
al9 confirming the presence of ECE-1 mRNA in diseased, but
not nondiseased, human arteries.
The endothelin system interacts with other vascular peptide and cytokine systems relevant to the progression of atherosclerosis. Previous reports have demonstrated antimitogenic actions of the natriuretic peptide system on endothelin-induced smooth muscle cell proliferation.14 Suenobo et al28 have recently defined the antiapoptotic actions of the natriuretic peptides and the proapoptotic actions of ET-1 in ECs. They proposed a counterregulatory role for these systems in the maintenance of EC turnover through apoptosis. The observation that stimulated macrophages release ET-129 30 and that ET-1 modulates macrophage chemotaxis31 supports important interactions between endothelin and other cellular components involved in cytokine production during atherogenesis. Our observation that ECE-1 is present and functionally active in atheromatous plaques contributes significantly to the body of evidence implicating the endothelin system in disease progression. The degree to which endothelin contributes to plaque progression as opposed to plaque initiation should be further investigated.
Kugiyama et al16 first demonstrated the antiatherogenic actions of chronic NEP-I in cholesterol-fed rabbits. We have confirmed this finding by demonstrating a nearly 50% reduction in aortic arch atheroma area in NEP-I–treated cholesterol-fed rabbits. The authors hypothesized that the mechanism of delayed atherogenesis involves inhibition of cardiac natriuretic peptide or substance P degradation. In the present study, ECE-1 was functionally active in atherosclerosis, and smooth muscle ECE-1 activity was attenuated by NEP-I in association with increased circulating cGMP concentrations. Although these actions were defined in the descending thoracic aorta, recent studies by Schwenke,32 who used a similar model, demonstrate that atheroma formation in the aortic arch and descending thoracic aorta occurs in parallel but at differing rates of accumulation. Therefore, it is reasonable to assume that the reductions in the aortic arch atheroma area were also present in the descending thoracic aorta in the present study.
The mechanism of attenuated ECE-1 activity remains undefined but was likely in part due to cGMP. In cultured bovine ECs, atrial natriuretic peptide inhibits ET-1 production and release.33 It is important to note that the time course of the big ET-1 contractions was not altered by chronic NEP-I or the presence of endothelium. This observation suggests that the concentration of ECE-1 available for substrate processing remained constant and that the affinity for the substrate or access to the substrate may have been impaired. Furthermore, the effect was not likely a nonspecific action of the NEP-I Candoxatril, inasmuch as this compound has been demonstrated to be specific for NEP34 and does not cross-react with ECE-1 in human tissue. The role of oxidized LDL in the regulation of ET-1 release and ECE-1 activity remains controversial.35 36 There were no differences in total serum cholesterol concentrations between the Athero and the NEP-I groups in the present study, suggesting that ECE-1 inhibition and attenuated atheroma formation by NEP-I occurred independent of alterations in lipids.
The present study used an assay of ECE-1 activity that may have been dependent on mechanical factors that participate in ET-1 release.37 However, there were no apparent differences in the mean arterial pressure or the degree of resting and maximal tension of the aortic rings between the groups that could explain the attenuated ECE-1 activity in the NEP-I group. Taken together, the data support a cGMP-related VSMC ECE-inhibiting action of NEP-I in atherosclerosis. This central conclusion is based on the inhibition of big ET-1–mediated arterial contraction in aortic rings denuded of the endothelium; this inhibition did not occur in aortic rings in which the endothelium was present. Further such reductions in big ET-1–mediated arterial contractions by NEP-I occurred in the absence of any alterations in the ET-1–mediated contractions, thus excluding any effective alteration in ET receptor sensitivity. Additional studies to define the kinetics of ECE-1 in the presence and absence of NEP-I and to investigate the intriguing possibility that NEP-I has divergent actions on endothelial and subendothelial ECE-1 will be required to further characterize the mechanism of ECE-1 inhibition observed in the present investigation.
Whereas NEP-I has been shown to inhibit the degradation of the natriuretic peptides, it has also been shown to inhibit ET-1 degradation, at least during acute administration.38 We observed no increase in circulating or tissue ET-1 concentrations but did show increased cGMP concentrations in the group treated with chronic oral NEP-I compared with the untreated Athero group. Together with the evidence suggesting attenuated ECE-1 activity by chronic NEP-I, the hypothesis that chronic NEP-I results in a net antiproliferative effect via the augmentation of natriuretic peptide concentrations or the enhanced cGMP-generating capacity of these proteins is plausible. These actions of chronic oral NEP-I further support the notion proposed by others that important interactions exist28 between the natriuretic peptide system and the endothelin system that have pathophysiological and potential therapeutic relevance in atherosclerosis. Indeed, the ability to inhibit the tissue ET-1 system in atherosclerosis, independent of effects on cholesterol lowering, also suggests the need to explore possible synergistic relations between NEP-I and lipid-lowering agents in the treatment of atherosclerosis.
|
Acknowledgments |
|---|
This study was supported by grants from the National Institutes of Health (HL-36634 and HL-07111), The Miami Heart Research Institute, The Mayo Foundation, and The Bruce and Ruth Rappaport Program in Vascular Biology. Candoxatril was provided by Dr Paul Barclay at Pfizer, Sandwich, UK. The authors gratefully acknowledge the technical support provided by Sharon Sandberg and Gail Hardy.
|
Footnotes |
|---|
Guest Editor for this article was Prof Michael J. Davies, St. Georges Hospital Medical School, London, UK.
Received August 10, 1999; revision received November 9, 1999; accepted November 19, 1999.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Hirata Y, Takagi Y, Fukuda Y, Marumo F. Endothelin is a potent mitogen for rat vascular smooth muscle cells. Atherosclerosis. 1989;78:225–228.[Medline] [Order article via Infotrieve]
2. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332:411–415.[Medline] [Order article via Infotrieve]
3. Lerman A, Edwards BS, Hallett JW, Heublein DM, Sandberg SM, Burnett JC Jr. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med. 1991;325:997–1001.[Abstract]
4. Kimura S, Kasuya Y, Sawamura T, Shinimi O, Sugita Y, Yanagisawa M, Goto K, Masaki T. Conversion of big endothelin-1 to 21-residue endothelin-1 is essential for expression of full vasoconstrictor activity: structure-activity relationships of big endothelin-1. J Cardiovasc Pharmacol. 1989;13:S5–S7,S18.
5. Opgenorth TJ, Wu-Wong JR, Shiosaki K. Endothelin-converting enzymes. FASEB J. 1992;6:2653–2659.[Abstract]
6. Schmidt M, Kroger B, Jacob E, Seulberger H, Subkowski T, Otter R, Meyer T, Schmalzing G, Hillen H. Molecular characterization of human and bovine endothelin converting enzyme (ECE-1). FEBS Lett. 1994;356:238–243.[Medline] [Order article via Infotrieve]
7. Lambert GL, Barker S, Corder R. Comparison of the regulation of endothelin-2 and endothelin-converting enzyme-1 b [correction of beta] by forskolin and TNF-alpha in ACHN cells [published erratum appears in J Cardiovasc Pharmacol. 1998;32:168]. J Cardiovasc Pharmacol. 1998;31:S49–S51.
8. Minamino T, Kurihara H, Takahashi M, Shimada K, Maemura K, Oda H, Ishikawa T, Uchiyama T, Tanzawa K, Yazaki Y. Endothelin-converting enzyme expression in the rat vascular injury model and human coronary atherosclerosis [published erratum appears in Circulation.. 1997;95:1975]. Circulation. 1997;95:221–230.
9.
Rossi GP, Colonna S, Pavan E, Albertin G, Della Rocca
F, Gerosa G, Csasratto D, Sartore S, Pauletto P, Pessina AC.
Endothelin-1 and its mRNA in the wall layers of human arteries ex vivo.
Circulation. 1999;99:1147–1155.
10.
Hirata K, Akita H, Yokoyama M, Watanabe Y. Impaired
vasodilatory response to atrial natriuretic peptide during
atherosclerosis progression. Arterioscler
Thromb. 1992;12:99–105.
11. Itoh H, Pratt RE, Dzau VJ. Atrial natriuretic polypeptide inhibits hypertrophy of vascular smooth muscle cells. J Clin Invest. 1990;86:1690–1697.
12. Grantham JA, Burnett JC Jr. Natriuretic peptides in cardiovascular disease: a focus on congestive heart failure. In: Levins SA, ed. Contemporary Endocrinology: The Natriuretic Peptides. Totowa, NJ: Humana Press Inc; 1997.
13. Uemasu J, Matsumoto H, Kitano M, Kawasaki H. Suppression of plasma endothelin-1 level by alpha-human atrial natriuretic peptide and angiotensin converting enzyme inhibition in normal men. Life Sci. 1993;53:969–974.[Medline] [Order article via Infotrieve]
14. Neuser D, Stasch JP, Knorr A, Kazda S. Inhibition by atrial natriuretic peptide of endothelin-1-stimulated proliferation of vascular smooth-muscle cells. J Cardiovasc Pharmacol. 1993;22:S257–S261.
15. Hanehira T, Kohno M, Yoshikawa J. Endothelin production in cultured vascular smooth muscle cells: modulation by the atrial, brain, and C-type natriuretic peptide system. Metabolism. 1997;46:487–493.[Medline] [Order article via Infotrieve]
16.
Kugiyama K, Sugiyama S, Matsumura T, Ohta Y, Doi H,
Yasue H. Suppression of atherosclerotic changes in
cholesterol-fed rabbits treated with an oral
inhibitor of neutral endopeptidase 24.11
(EC 3.4.24.11). Arterioscler Thromb Vasc Biol. 1996;16:1080–1087.
17. Grantham JA, Schirger JA, Williamson EE, Heublein DM, Wennberg PW, Kirchengast M, Muenter K, Subkowski T, Burnett JC Jr. Enhanced endothelin-converting enzyme immunoreactivity in early atherosclerosis. J Cardiovasc Pharmacol. 1998;31:S22–S26.
18. Danilewicz JC, Barclay PL, Barnish IT, Brown D, Campbell SF, James K, Samuels GM, Terrett NK, Wythes MJ. UK-69,578, a novel inhibitor of EC 3.4.24.11 which increases endogenous ANF levels and is natriuretic and diuretic. Biochem Biophys Res Commun. 1989;164:58–65.[Medline] [Order article via Infotrieve]
19.
Borgeson DD, Grantham JA, Williamson EE, Luchner A,
Redfield MM, Opgenorth TJ, Burnett JC Jr. Chronic oral endothelin type
A receptor antagonism in experimental heart failure.
Hypertension. 1998;31:766–770.
20.
Grantham JA, Borgeson DD, Burnett JC Jr. BNP:
pathophysiological and potential therapeutic roles
in acute congestive heart failure. Am J Physiol. 1997;272:R1077–R1083.
21. Brattsand R. Distribution of cholesterol and triglycerides among lipoprotein fractions in fat-fed rabbits at different levels of serum cholesterol. Atherosclerosis. 1976;23:97–110.[Medline] [Order article via Infotrieve]
22. Roach MR, Fletcher J, Cornhill JF. The effect of the duration of cholesterol feeding on the development of sudanophilic lesions in the rabbit aorta. Atherosclerosis. 1976;25:1–11.[Medline] [Order article via Infotrieve]
23. Salomone OA, Elliott PM, Calvino R, Holt D, Kaski JC. Plasma immunoreactive endothelin concentration correlates with severity of coronary artery disease in patients with stable angina pectoris and normal ventricular function. J Am Coll Cardiol. 1996;28:14–19.[Abstract]
24.
Shimada K, Takahashi M, Tanzawa K. Cloning and
functional expression of endothelin-converting enzyme from rat
endothelial cells. J Biol Chem. 1994;269:18275–18278.
25. Shimada K, Takahashi M, Ikeda M, Tanzawa K. Identification and characterization of two isoforms of an endothelin- converting enzyme-1. FEBS Lett. 1995;371:140–144.[Medline] [Order article via Infotrieve]
26. Shimada K, Matsushita Y, Wakabayashi K, Takahashi M, Matsubara A, Iijima Y, Tanzawa K. Cloning and functional expression of human endothelin-converting enzyme cDNA. Biochem Biophys Res Commun. 1995;207:807–812.[Medline] [Order article via Infotrieve]
27. Subkowski T, Hillen H, Kroger B, Schmidt M. Monoclonal antibodies against human endothelin-converting enzyme-1. J Immunoassay. 1998;19:75–93.[Medline] [Order article via Infotrieve]
28.
Suenobo N, Shichiri M, Iwashina M, Marumo F, Hirata Y.
Natriuretic peptides and nitric oxide induce
endothelial apoptosis via cGMP-dependent
mechanism. Arterioscler Thromb Vasc Biol. 1999;19:140–146.
29.
Ehrenreich H, Anderson RW, Fox CH, Rieckmann P, Hoffman
GS, Travis WD, Coligan JE, Kehrl JH, Fauci AS. Endothelins, peptides
with potent vasoactive properties, are produced by human
macrophages. J Exp Med. 1990;172:1741–1748.
30. He Y, Kwan WC, Steinbrecher UP. Effects of oxidized low density lipoprotein on endothelin secretion by cultured endothelial cells and macrophages. Atherosclerosis. 1996;119:107–118.[Medline] [Order article via Infotrieve]
31. Achmad TH, Rao GS. Chemotaxis of human blood monocytes toward endothelin-1 and the influence of calcium channel blockers. Biochem Biophys Res Commun. 1992;189:994–1000.[Medline] [Order article via Infotrieve]
32.
Schwenke DC. Comparison of aorta and pulmonary
artery, I: early cholesterol accumulation and relative
susceptibility to atheromatous lesions. Circ
Res. 1997;81:338–345.
33.
Hu RM, Levin ER, Pedram A, Frank HJ. Atrial
natriuretic peptide inhibits the production and
secretion of endothelin from cultured endothelial
cells: mediation through the C receptor. J Biol Chem. 1992;267:17384–17389.
34. Danilewicz JC, Barclay PL, Barnish IT. UK-69578, a novel inhibitor of EC 3.4.24.11 which increases endogenous ANF levels and is natriuretic and diuretic. Biochem Biophys Res Commun. 1989;164:58–65.
35.
Boulanger CM, Tanner FC, Bea ML, Hahn AW, Werner A,
Luscher TF. Oxidized low density lipoproteins induce mRNA expression
and release of endothelin from human and porcine
endothelium. Circ Res. 1992;70:1191–1197.
36.
Jougasaki M, Kugiyama K, Saito Y, Nakao K, Imura H,
Yasue H. Suppression of endothelin-1 secretion by
lysophosphatidylcholine in oxidized low density lipoprotein in cultured
vascular endothelial cells. Circ Res. 1992;71:614–619.
37.
Hasdai D, Holmes DR Jr, Garratt KN, Edwards WD, Lerman
A. Mechanical pressure and stretch release endothelin-1 from human
atherosclerotic coronary arteries in vivo.
Circulation. 1997;95:357–362.
38. McDowell G, Coutie W, Shaw C, Buchanan KD, Struthers AD, Nicholls DP. The effect of the neutral endopeptidase inhibitor drug, Candoxatril, on circulating levels of two of the most potent vasoactive peptides. Br J Clin Pharmacol. 1997;43:329–332.[Medline] [Order article via Infotrieve]
This article has been cited by other articles:
 |
|
 |
|
  M. N. Barber, M. Kanagasundaram, C. R. Anderson, L. M. Burrell, and R. L. Woods Vascular neutral endopeptidase inhibition improves endothelial function and reduces intimal hyperplasia Cardiovasc Res, July 1, 2006; 71(1): 179 - 188. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Sansoe, M. Aragno, R. Mastrocola, J. C. Cutrin, S. Silvano, G. Mengozzi, A. Smedile, F. Rosina, O. Danni, and M. Rizzetto Overexpression of kidney neutral endopeptidase (EC 3.4.24.11) and renal function in experimental cirrhosis Am J Physiol Renal Physiol, June 1, 2006; 290(6): F1337 - F1343. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-D. Orzechowski, A. Gunther, S. Menzel, A. Zimmermann, H. Funke-Kaiser, R. Real, T. Subkowski, F. S. Zollmann, and M. Paul Transcriptional Mechanism of Protein Kinase C-Induced Isoform-Specific Expression of the Gene for Endothelin-Converting Enzyme-1in Human Endothelial Cells Mol. Pharmacol., December 1, 2001; 60(6): 1332 - 1342. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. W. TAAL, V. D. NENOV, W. WONG, S. R. SATYAL, O. SAKHAROVA, J. H. CHOI, J. L. TROY, and B. M. BRENNER Vasopeptidase Inhibition Affords Greater Renoprotection than Angiotensin-Converting Enzyme Inhibition Alone J. Am. Soc. Nephrol., October 1, 2001; 12(10): 2051 - 2059. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Burrell, N. K. Farina, L. C. Balding, and C. I. Johnston Beneficial Renal and Cardiac Effects of Vasopeptidase Inhibition With S21402 in Heart Failure Hypertension, December 1, 2000; 36(6): 1105 - 1111. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||